Patient annual OOP spending is capped to SEK 2 200 (USD 250). Co-payment is increased to 20% for off-patent drugs with cheaper (generic) alternatives. Scotland: no co-payment. The standard benefit in 2014 has a USD 310 deductible and 25% coinsurance up to an initial coverage limit of $2,850 in total drug costs, followed by a coverage gap.